Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781-810. [
Link] [
DOI:10.1146/annurev.cellbio.20.010403.113126]
Baarsma HA, Königshoff M, Gosens R. The WNT signaling pathway from ligand secretion to gene transcription: Molecular mechanisms and pharmacological targets. Pharmacol Ther. 2013;138(1):66-83. [
Link] [
DOI:10.1016/j.pharmthera.2013.01.002]
Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev. 2007;17(1):45-51. [
Link] [
DOI:10.1016/j.gde.2006.12.007]
Herr P, Hausmann G, Basler K. WNT secretion and signalling in human disease. Trends Mol Med. 2012;18(8):483-93. [
Link] [
DOI:10.1016/j.molmed.2012.06.008]
Brown AM. Wnt signaling in breast cancer: Have we come full circle?. Breast Cancer Res. 2001;3(6):351-5. [
Link] [
DOI:10.1186/bcr321]
Liu CC, Prior J, Piwnica-Worms D, Bu G. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci USA. 2010;107(11):5136-41. [
Link] [
DOI:10.1073/pnas.0911220107]
Howe LR, Brown AM. Wnt signaling and breast cancer. Cancer Biol Ther. 2004;3(1):36-41. [
Link] [
DOI:10.4161/cbt.3.1.561]
Benhaj K, Akcali KC, Ozturk M. Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol Rep. 2006;15(3):701-7. [
Link]
Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP Henley SJ, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290-314. [
Link]
Hsieh JC, Lee L, Zhang L, Wefer S, Brown K, DeRossi C, et al. Mesd encodes an LRP5/6 chaperone essential for specification of mouse embryonic polarity. Cell. 2003;112(3):355-67. [
Link]
Lu W, Liu CC, Thottassery JV, Bu G, Li Y. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/β-catenin signaling in cancer cells. Biochemistry. 2010;49(22):4635-43. [
Link] [
DOI:10.1021/bi1001486]
Deshpande N, Addess KJ, Bluhm WF, Merino-Ott JC, Townsend-Merino W, Zhang Q, et al. The RCSB protein data bank: A redesigned query system and relational database based on the mmCIF schema. Nucleic Acids Res. 2005;33(Database issue):D233-7. [
Link]
Vriend G. What if: A molecular modeling and drug design program. J Mol Graph. 1990;8(1):52-6. [
Link] [
DOI:10.1016/0263-7855(90)80070-V]
Haile JM. Molecular dynamics simulation: Elementary methods. New York: Wiley; 1992. [
Link]
Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang RE, Duke RE, et al. Amber 10 user's manual [Internet]. California: University of California; 2008 [cited 2018 May 25]. Available from: http://glycam.org/legacy_courses/2010/8330/pdfs/Amber10i.pdf. [
Link]
Liu CC, Pearson C, Bu G. Cooperative folding and ligand-binding properties of LRP6 β-propeller domains. J Biol Chem. 2009;284(22):15299-307. [
Link] [
DOI:10.1074/jbc.M807285200]
Bourhis E, Tam C, Franke Y, Bazan JF, Ernst J, Hwang J, et al. Reconstitution of a frizzled8.Wnt3a.LRP6 signaling complex reveals multiple Wnt and Dkk1 binding sites on LRP6. J Biol Chem. 2010;285(12):9172-9. [
Link]
Lin C, Lu W, Zhang W, Londo-o-Joshi AI, Buchsbaum DJ, Bu G, et al. The C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/β-catenin signaling in cancer cells. PloS One. 2013;8(2):e58102. [
Link]
Köhler C, Lighthouse JK, Werther T, Andersen OM, Diehl A, Schmieder P, et al. The structure of MESD45–184 brings light into the mechanism of LDLR family folding. Structure. 2011;19(3):337-48. [
Link]
